16 Tidholm A, Ljungvall I, Hoglund AB, Westling AB, Haggstrom J. Tissue Doppler and Strain Imaging in Dogs with
Myxomatous Mitral Valve Disease in Different Stages of Congestive Heart Failure.
Parker, H. G. and Kilroy - Glynn, P. (1016),
Myxomatous mitral valve disease in dogs: Does size matter?
«Left Atrial Rupture Secondary to
Myxomatous Mitral Valve Disease in 11 dogs.»
Not exact matches
In the QUEST Study, pimobendan significantly increased the survival time of dogs with congestive heart failure (CHF) caused by
myxomatous mitral valve disease (MMVD).
Effect of pimobendan or benazepril hydrochloride on survival times
in dogs with congestive heart failure caused by naturally occurring
myxomatous mitral valve disease: the QUEST Study.
To determine whether chronic oral administration of pimobendan
in dogs with evidence of increased heart size secondary to preclinical
myxomatous mitral valve disease (MMVD) can delay the onset of clinical signs of congestive heart failure (CHF).1
In the VetSCOPE Study, pimobendan rapidly improved the quality of life in dogs with CHF caused by myxomatous mitral valve disease (MMVD
In the VetSCOPE Study, pimobendan rapidly improved the quality of life
in dogs with CHF caused by myxomatous mitral valve disease (MMVD
in dogs with CHF caused by
myxomatous mitral valve disease (MMVD).
Effect of Pimobendan
in Dogs with Preclinical
Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study — A Randomized Clinical Trial.
Effect of pimobendan
in dogs with preclinical
myxomatous mitral valve disease and cardiomegaly: the EPIC Study - a randomized clinical trial.
The EPIC Study showed a significant benefit
in administering pimobendan
in dogs with preclinical
myxomatous mitral valve disease (MMVD)-- before the onset of congestive heart failure (CHF) cardiac - related death, or euthanasia (composite primary endpoint).
This groundbreaking study sought to answer a key question: Can pimobendan — with proven efficacy
in treating dogs with congestive heart failure (CHF) caused by
myxomatous mitral valve disease (MMVD)-- also delay the onset of CHF caused by MMVD?
The EPIC (Evaluation of Pimobendan
In dogs with Cardiomegaly) Study1 analysed whether long - term administration of pimobendan to dogs with stage B2
myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement will delay onset of clinical signs of congestive heart failure (CHF), cardiac - related death, or euthanasia (composite primary endpoint).
The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema
in dogs with congestive heart failure (CHF) caused by
myxomatous mitral valve disease (MMVD).
The
disease which causes the thickening and distortion of the
mitral valve is known as
myxomatous mitral valve disease and we will talk about this common condition some more
in future articles.
The trial, titled «Effect of Pimobendan
in Dogs with Preclinical
Myxomatous Mitral Valve Disease (MMVD) and Cardiomegaly» (EPIC), is the largest clinical study ever to be conducted
in veterinary cardiology.
Overview
Myxomatous mitral valve degeneration (MMVD) is the most common acquired type of heart
disease and new murmurs
in older dogs.
Mitral regurgitation (MR), secondary to myxomatous mitral valve disease (MMVD), is the most common cardiac disorder in dogs and is usually caused by progressive degeneration of the atrioventricular v
Mitral regurgitation (MR), secondary to
myxomatous mitral valve disease (MMVD), is the most common cardiac disorder in dogs and is usually caused by progressive degeneration of the atrioventricular v
mitral valve disease (MMVD), is the most common cardiac disorder
in dogs and is usually caused by progressive degeneration of the atrioventricular
valves.
Myxomatous degeneration of the
mitral valve (MMVD) accounts for nearly 75 percent of all heart problems seen by veterinarians, making it the most common heart
disease diagnosed
in dogs.
Effect of pimobendan or benazepril hydrochloride on survival times
in dogs with congestive heart failure caused by naturally occurring
myxomatous mitral valve disease: the QUEST study.